|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Glaxo Wellcome |
|---|---|
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00008554 |
Purpose
The purpose of this study is to compare GW433908 and nelfinavir when each is given with abacavir and lamivudine to HIV patients who have not taken antiretroviral drugs.
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Infections |
Drug: Abacavir sulfate Drug: Nelfinavir mesylate Drug: Lamivudine Drug: GW433908 |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Primary Purpose: Treatment |
| Official Title: | A Phase III, Randomised, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of GW433908 (1400 Mg Bid) and Nelfinavir (1250 Mg Bid) Over 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Adults |
| Estimated Enrollment: | 210 |
| Study Start Date: | November 2000 |
Patients are randomized in a 2:1 scheme to 1 of 2 treatment groups. Group 1 receives GW433908 plus abacavir (ABC) plus lamivudine (3TC); Group 2 receives nelfinavir (NFV) plus ABC plus 3TC. Patients undergo safety and efficacy assessments at the Screening Visit, Day 1 (Entry), and Weeks 1, 2, 4, 8, 12, 16, 20, 24, and every 8 weeks thereafter. A follow-up visit is performed 4 weeks after the permanent discontinuation of study drug. Detailed assessments for the development of lipodystrophy/fat redistribution occur at Day 1, Week 24, Week 48, and every 16 weeks thereafter. Patients have examinations and laboratory tests performed at visits.
Eligibility| Ages Eligible for Study: | 13 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients may be eligible for this study if they:
Exclusion Criteria
Patients will not be eligible for this study if they:
Contacts and Locations| United States, California | |
| East Bay Clinical Trial Ctr | |
| Concord, California, United States, 94520 | |
| Ocean View Internal Medicine | |
| Long Beach, California, United States, 90803 | |
| United States, Florida | |
| Florida ID Group | |
| Orlando, Florida, United States, 32801 | |
| Clinical Pharmacology Services | |
| Tampa, Florida, United States, 33617 | |
| Hillsborough County Health Dept | |
| Tampa, Florida, United States, 33602 | |
| United States, Illinois | |
| Veterans Affairs Med Ctr of North Chicago | |
| Chicago, Illinois, United States, 60064 | |
| United States, Kansas | |
| Univ of Kansas Med Ctr | |
| Kansas City, Kansas, United States, 661607415 | |
| United States, New Jersey | |
| UMDNJ - New Jersey Med School | |
| Newark, New Jersey, United States, 071032757 | |
| Saint Michael's Med Ctr | |
| Newark, New Jersey, United States, 07102 | |
| United States, New York | |
| Bronx Municipal Hosp Ctr/Jacobi Med Ctr | |
| Bronx, New York, United States, 10461 | |
| Brookdale Univ Hosp and Med Ctr | |
| Brooklyn, New York, United States, 112123198 | |
| Addiction Research and Treatment Corp | |
| Brooklyn, New York, United States, 11201 | |
| Howard Grossman | |
| New York, New York, United States, 10011 | |
| Mount Sinai School of Medicine | |
| New York, New York, United States, 10029 | |
| Gervais Frechette | |
| New York, New York, United States, 10011 | |
| Univ of Rochester Med Ctr | |
| Rochester, New York, United States, 14642 | |
| United States, North Carolina | |
| SMO-USA Inc | |
| Charlotte, North Carolina, United States, 28211 | |
| United States, Oregon | |
| Advanced Clinical Trials Inc | |
| Eugene, Oregon, United States, 97401 | |
| United States, Pennsylvania | |
| Thomas Jefferson Univ | |
| Philadelphia, Pennsylvania, United States, 19107 | |
| United States, Texas | |
| Univ of Texas Med Branch | |
| Galveston, Texas, United States, 775550835 | |
| MacGregor Med Association | |
| Houston, Texas, United States, 77054 | |
| Walter Gaman | |
| Irving, Texas, United States, 75038 | |
| Southwest Texas Methodist Hosp | |
| San Antonio, Texas, United States, 78229 | |
More Information
| ClinicalTrials.gov Identifier: | NCT00008554 History of Changes |
| Other Study ID Numbers: | 316A, APV30001 |
| Study First Received: | January 13, 2001 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Food and Drug Administration |
|
HIV-1 Drug Therapy, Combination HIV Protease Inhibitors Lamivudine |
Nelfinavir Reverse Transcriptase Inhibitors Anti-HIV Agents abacavir |
|
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases HIV Protease Inhibitors Nelfinavir Fosamprenavir |
Lamivudine Reverse Transcriptase Inhibitors Abacavir Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Therapeutic Uses Nucleic Acid Synthesis Inhibitors |